Marta Lembicz

Marta Lembicz

Auto-generated profile, based on publicly available information

Marta Lembicz

Poznan University of Medical Sciences

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2018 in Medical Oncology
Verified
Journal Article
Open access
PDF file
JRJoanna Rupa-Matysek
Joanna Rupa-Matysek
MLMarta Lembicz
Marta Lembicz
EREliza Katarzyna Rogowska
Eliza Katarzyna Rogowska
LGLidia Gil
Lidia Gil
MKMieczysław Komarnicki
Mieczysław Komarnicki
HBHalina Batura-Gabryel
Halina Batura-Gabryel
The aim of the study was to investigate the prognostic significance of selected risk assessment models (RAMs) for predicting venous thromboembolism (VTE) events in patients undergoing outpatient chemotherapy for lung cancer. We evaluated the following VTE-risk assessment tools: Khorana risk score (KRS), PROTECHT score, CONKO score and COMPASS-cancer-associated thrombosis score (COMPASS-CAT). Retrospective analyses were performed on 118 patients with lung cancer, 20 of whom developed VTE with a median of 2.5 months from diagnosis. Patients receiving gemcitabine-based regimen (25%), patients with a history of atrial fibrillation (AF) and patients with chronic kidney disease developed VTE more often than other patients. In the multivariate analysis, high COMPASS-CAT score (OR 8.73; 95% CI 1.01–75.22, P = 0.049), gemcitabine chemotherapy (OR 3.37; 95% CI 1.09–10.39, P = 0.035) and AF (OR 7.19; 95% CI 1.89–27.33, P = 0.004) were all significantly associated with VTE development. VTE occurred in; 13% (n = 2) of the KRS high-risk group, 17.7% (n = 11) of the PROTECHT high-risk group, 15% (n = 4) of the CONKO high-risk group and 23.8% (n = 20) of the COMPASS-CAT high-risk group (n = 84). Only the COMPASS-CAT score was able to identify 100% of patients who developed VTE, and best discriminated between patients with high and low risk of VTE development (C statistic 0.89). The ROC analysis indicated a cutoff value of 11 points (95% CI 0.821–0.962) for COMPASS-CAT for VTE development in patients with lung cancer. In conclusion, in our study of all the VTE–RAMs analyzed, the COMPASS-CAT model was the most accurate predictor of VTE development in patients with lung cancer.

1 January 2018 in Annals of Thoracic Medicine
Verified
Journal Article
Open access
PDF file
MLMarta Lembicz
Marta Lembicz
Piotr GabryelPiotr Gabryel
Piotr Gabryel
BBBeata Brajer-Luftmann
Beata Brajer-Luftmann
WDWojciech Dyszkiewicz
Wojciech Dyszkiewicz
HBHalina Batura-Gabryel
Halina Batura-Gabryel
INTRODUCTION: Radical surgical treatment is the preferred action for patients with early-stage non-small cell lung cancer (NSCLC). Qualification for surgical treatment should consider a risk associated with the effect of comorbidities on the general condition of the patient. The aim of this article was an attempt to identify the risk factors for postoperative complications in patients treated for NSCLC, with a special focus on the coexisting diseases. METHODS: A total of 400 patients with NSCLC were included in this retrospective study. The incidence of postoperative complications (including major complications according to the European Society of Thoracic Surgeons [ESTS]) was analyzed. Factors associated with high risk of postoperative complications were identified. RESULTS: Postoperative complications occurred in 151 patients (39% operated patients), including severe complications according to ESTS in 75 patients (19%). From univariate analysis, risk factors for postoperative complications were arrhythmias, pneumonectomy, and open thoracotomy. According to ESTS, for major complications, the risk factors included age ≥65 years, the presence of comorbidities, hypertension, and arrhythmias. From multivariate analysis, the risk of complications was higher in patients undergoing pneumonectomy and with cardiac arrhythmias, whereas the risk of serious complications according to ESTS was found in people ≥65 years of age and suffering from comorbidities. CONCLUSIONS: The risk of postoperative complications is affected by both surgical factors and the general health of the patient. Elderly patients with chronic disease history, hypertension, and arrhythmias have an increased risk of postoperative complications. Knowledge of these factors will identify a group of patients requiring internal consultation and optimization of preoperative treatment and postoperative follow-up.

20 December 2013 in Advances in Respiratory Medicine
Verified
Journal Article
Open access
MLMarta Lembicz
Marta Lembicz
HBHalina Batura-Gabryel
Halina Batura-Gabryel
ANAgata Nowicka
Agata Nowicka
Ziarniniakowatość z zapaleniem naczyń (GPA) jest rzadką chorobą o nieznanej etiologii, cechującą się martwiczym zapaleniem małych i średnich naczyń oraz tworzeniem ziarniniaków. Choroba typowo zajmuje górne i dolne drogi oddechowe oraz nerki, może jednak występować w wielu innych lokalizacjach narządowych, dając często zaskakujący obraz kliniczny. U większości pacjentów stwierdza się autoprzeciwciała przeciwko cytoplazmie neutrofilów (ANCA), którym przypisuje się rolę patogenetyczną. Choroba dotyczy najczęściej osób w średnim i starszym wieku, z przewagą rasy białej. Przed erą leczenia immunosupresyjnego GPA była chorobą o wysokiej wczesnej śmiertelności. Obecnie dysponujemy leczeniem, które pozwala na uzyskanie remisji u większości chorych. Decyzję co do sposobu leczenia podejmuje się w zależności od postaci klinicznej choroby (miejscowa, uogólniona, oporna). Standardem w leczeniu indukującym remisję w postaciach uogólnionych choroby jest cyklofosfamid w połączeniu ze steroidoterapią. Taka terapia, jakkolwiek skuteczna, obarczona jest wieloma działaniami niepożądanymi. Ponadto, część chorych wykazuje oporność na standardowe leczenie, a połowa z nich doświadcza nawrotów choroby. Dlatego poszukuje się alternatywnych metod leczenia indukującego remisję oraz skutecznego leczenia podtrzymującego po jej uzyskaniu. Obecnie duże nadzieje budzą wprowadzone od kilku lat do terapii GPA leki biologiczne. Wśród nich dotychczas najlepiej przebadanym preparatem jest rytuksymab, który znalazł miejsce w zaleceniach EULAR, jako lek alternatywny dla chorych z postacią oporną GPA. W artykule omówiono obraz kliniczny GPA, zasady jej rozpoznawania oraz aktualnie zalecane postępowanie.

Verified
Journal Article
Open access
PDF file
MLMarta Lembicz
Marta Lembicz
Piotr GabryelPiotr Gabryel
Piotr Gabryel
BBBeata Brajer-Luftmann
Beata Brajer-Luftmann
WDWojciech Dyszkiewicz
Wojciech Dyszkiewicz
HBHalina Batura-Gabryel
Halina Batura-Gabryel
INTRODUCTION: In the recent years comorbidity has been discussed as a factor affecting therapeutic decisions, the course of treatment, and prognosis of patients with lung cancer. The aim of the study was 1. to evaluate the occurrence of comorbidities in patients with lung cancer undergoing surgery, and 2. to investigate the utility of Charlson Comorbidity Index (CCI) and Simplified Comorbidity Score (SCS) for preoperative evaluation of Polish patients with lung cancer. MATERIAL AND METHODS: The retrospective study included 476 patients with lung cancer, who underwent surgical treatment. In all patients, data on histopathological type of the tumor, stage, history of smoking, comorbidities, and spirometric parameters were collected. CCI and SCS scores were calculated. The presence of comorbidities was analyzed in relation to sex, histology, and stage of lung cancer. Correlations between CCI and SCS scores and age, number of pack-years, spirometric parameters were assessed. RESULTS: The most prevalent comorbidities were hypertension (42%), chronic obstructive pulmonary disease (COPD) (22%), coronary heart disease (17%), and diabetes (12%). There were no differences in the distribution of comorbidity depending on the histological type and stage of lung cancer. The CCI and SCS scores showed correlations with age, number of pack-years and spirometric parameters, however, their compounds do not reflect the profile of most prevalent comoribidities. CONCLUSION: The burden of comorbidity among patients with lung cancer is significant. Comorbidity should be assessed while considering patients for surgical treatment. However, the CCI and SCS do not seem precise enough for this purpose. INTRODUCTION: In the recent years comorbidity has been discussed as a factor affecting therapeutic decisions, the course of treatment, and prognosis of patients with lung cancer. The aim of the study was 1. to evaluate the occurrence of comorbidities in patients with lung cancer undergoing surgery, and 2. to investigate the utility of Charlson Comorbidity Index (CCI) and Simplified Comorbidity Score (SCS) for preoperative evaluation of Polish patients with lung cancer. MATERIAL AND METHODS: The retrospective study included 476 patients with lung cancer, who underwent surgical treatment. In all patients, data on histopathological type of the tumor, stage, history of smoking, comorbidities, and spirometric parameters were collected. CCI and SCS scores were calculated. The presence of comorbidities was analyzed in relation to sex, histology, and stage of lung cancer. Correlations between CCI and SCS scores and age, number of pack-years, spirometric parameters were assessed. RESULTS: The most prevalent comorbidities were hypertension (42%), chronic obstructive pulmonary disease (COPD) (22%), coronary heart disease (17%), and diabetes (12%). There were no differences in the distribution of comorbidity depending on the histological type and stage of lung cancer. The CCI and SCS scores showed correlations with age, number of pack-years and spirometric parameters, however, their compounds do not reflect the profile of most prevalent comoribidities. CONCLUSION: The burden of comorbidity among patients with lung cancer is significant. Comorbidity should be assessed while considering patients for surgical treatment. However, the CCI and SCS do not seem precise enough for this purpose.